Algeta's Financial Calendar 2012
(Thomson Reuters ONE) -
Oslo, Norway, 7 November 2011 - Algeta ASA (OSE: ALGETA), a company focused on
the development of novel targeted cancer therapeutics, announces its financial
calendar for 2012:
4(th) Quarter Results 2011: 9 February 2012
1(st) Quarter Results 2012: 3 May 2012
2(nd) Quarter Results 2012: 16 August 2012
3(rd) Quarter Results 2012: 15 November 2012
Annual General Meeting: 19 April 2012
All dates are tentative and subject to changes.
###
For further information, please contact:
Algeta ASA:
Mike Booth +47 2202 4510
Communications & Corporate Affairs ir(at)algeta.com
International media enquiries:
Mark Swallow +44 207 638 9571
Citigate Dewe Rogerson mark.swallow(at)citigatedr.co.uk
US investor enquiries:
Jessica Lloyd +1 646 378 2928
The Trout Group jlloyd(at)troutgroup.com
About Algeta
Algeta is a company focused on developing novel targeted therapies for patients
with cancer based on its alpha-pharmaceutical platform.
Algeta's lead product Alpharadin (radium-223 chloride) is a first-in-class,
highly targeted alpha-pharmaceutical under clinical evaluation to improve
survival in patients with bone metastases from advanced cancer. Its localized
action helps preserve the surrounding healthy tissue thereby limiting side-
effects.
Alpharadin is being developed under a development and commercialization
agreement with Bayer HealthCare Pharmaceuticals AG. In June 2011, a global phase
III clinical trial (ALSYMPCA) of Alpharadin to treat bone metastases in patients
with castration-resistant prostate cancer (CRPC) was stopped early after meeting
its primary endpoint of significantly improving overall survival. The US Food
and Drug Administration (FDA) has granted Alpharadin Fast Track designation for
this indication. Alpharadin is also under investigation in phase II clinical
trials as a potential new treatment for bone metastases in endocrine-refractory
breast cancer patients, and in a phase I/IIa trial in combination with docetaxel
chemotherapy in for bone metastases CRPC patients.
The development of bone metastases represents a serious development for cancer
patients as they are associated with a dramatic decline in patient health and
quality of life, ultimately leading to death. Bone metastases represent a major
unmet medical need, occurring frequently in certain late-stage cancers, e.g.
prostate (in up to 90% patients), breast (up to 75%) and lung (up to 40%).
Algeta is also exploring the potential of Targeted Thorium Conjugates (TTCs),
which are based on conjugating the alpha-emitter thorium-227 to targeting
molecules, as a basis of a future pipeline of tumor-targeting alpha-
pharmaceutical candidates.
The Company is headquartered in Oslo, Norway, and is listed on the Oslo Stock
Exchange (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Forward-looking Statement
This news release contains forward-looking statements and forecasts based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of operations and the financial condition of Algeta. There are a number of
factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements. These
factors include, among other things, risks associated with technological
development, the risk that research & development will not yield new products
that achieve commercial success, the impact of competition, the ability to close
viable and profitable business deals, the risk of non-approval of patents not
yet granted and difficulties of obtaining relevant governmental approvals for
new products.
###
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Algetas Financial Calendar 2012:
http://hugin.info/134655/R/1560315/482691.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Algeta ASA via Thomson Reuters ONE
[HUG#1560315]
Unternehmensinformation / Kurzprofil:
Datum: 07.11.2011 - 08:00 Uhr
Sprache: Deutsch
News-ID 84387
Anzahl Zeichen: 5491
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 181 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Algeta's Financial Calendar 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
Algeta ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
